Literature DB >> 2227796

Binding of low density lipoprotein (LDL) to C-reactive protein (CRP): a possible binding through apolipoprotein B in LDL at phosphorylcholine-binding site of CRP.

W Nunomura1, M Hatakeyama.   

Abstract

Healthy human serum reacted with C-reactive protein of human (hCRP) or rat (rCRP) immobilized on Sepharose 4B in the presence of Ca2+. The bound serum proteins were eluted with 0.1 M ethylenediaminetetraacetic acid, trisodium salt (EDTA) dissolved in 10 mM Tris-HCl buffer, pH 8.0, containing 140 mM NaCl. The eluted proteins from the hCRP column was found to be low density lipoprotein (LDL), 90% of its protein being apo B. The one from the rCRP column contained also apo B by 36.7%. The effect of phosphorylcholine (PC), phosphorylethanolamine, phosphorylserine, galactose and high density lipoprotein (HDL) on the binding of LDL and apo B to CRP was investigated by enzyme-linked immunosorbent assay. Among them, only PC strongly inhibited the binding. One of the two available mouse monoclonal antibodies to hCRP (#19), which interferes with the binding of PC to CRP molecule, prevented CRP from binding LDL or apo B. In contrast, the other antibody (#17), which does not affect the binding of PC to CRP, did not inhibit the binding of LDL or apo B to CRP. It was therefore concluded that LDL binds to CRP by apo B moiety at the PC-binding site of CRP molecule.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2227796

Source DB:  PubMed          Journal:  Hokkaido Igaku Zasshi        ISSN: 0367-6102


  11 in total

1.  Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response.

Authors:  Stanley L Hazen; Guy M Chisolm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

2.  Atherosclerosis-related functions of C-reactive protein.

Authors:  Alok Agrawal; David J Hammond; Sanjay K Singh
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2010-12-01

Review 3.  The connection between C-reactive protein and atherosclerosis.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Bhavya Voleti; Alok Agrawal
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

4.  Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  Clin Chim Acta       Date:  2008-04-27       Impact factor: 3.786

5.  C-reactive protein-bound enzymatically modified low-density lipoprotein does not transform macrophages into foam cells.

Authors:  Sanjay K Singh; Madathilparambil V Suresh; Deborah C Prayther; Jonathan P Moorman; Antonio E Rusiñol; Alok Agrawal
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

Review 6.  A hypothesis resolving the apparently disparate activities of native and altered forms of human C-reactive protein.

Authors:  M J Shields
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 7.  Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.

Authors:  Filipe Seguro Paula; José Delgado Alves
Journal:  Biologics       Date:  2013-12-09

8.  Obesity associated molecular forms of C-reactive protein in human.

Authors:  Bela F Asztalos; Michael S Horan; Katalin V Horvath; Ann Y McDermott; Naga P Chalasani; Ernst J Schaefer
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

9.  Effect of CRP on Some of the in vitro Physicochemical Properties of LDL.

Authors:  Hashem Nayeri; Gholam Ali Naderi; Masoud Saleh Moghadam; Samaneh Mohamadzadeh; Maryam Boshtam; Narges Jafari Dinani; Adel Abedpour Dehkordi
Journal:  ARYA Atheroscler       Date:  2010

Review 10.  Recognition functions of pentameric C-reactive protein in cardiovascular disease.

Authors:  Alok Agrawal; Toh B Gang; Antonio E Rusiñol
Journal:  Mediators Inflamm       Date:  2014-05-19       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.